FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2113457384> ?p ?o ?g. }

• W2113457384 abstract "A small number of individuals with B-cell-related primary immunodeficiency diseases (PIDs) may exhibit long-term (prolonged or chronic) excretion of immunodeficiency-associated vaccine-derived polioviruses (iVDPVs) following infection with oral poliovirus vaccine (OPV). These individuals pose a risk of live poliovirus reintroduction into the population after global wild poliovirus eradication and subsequent OPV cessation. Treatment with polio antiviral drugs may potentially stop excretion in some of these individuals and thus may reduce the future population risk. We developed a discrete event simulation model to characterize the global prevalence of long-term iVDPV excretors based on the best available evidence. We explored the impact of different assumptions about the effectiveness of polio antiviral drugs and the fraction of long-term excretors identified and treated. Due to the rarity of long-term iVDPV excretion and limited data on the survival of PID patients in developing countries, uncertainty remains about the current and future prevalence of long-term iVDPV excretors. While the model suggests only approximately 30 current excretors globally and a rapid decrease after OPV cessation, most of these excrete asymptomatically and remain undetected. The possibility that one or more PID patients may continue to excrete iVDPVs for several years after OPV cessation represents a risk for reintroduction of live polioviruses after OPV cessation, particularly for middle-income countries. With the effectiveness of a single polio antiviral drug possibly as low as 40 % and no system in place to identify and treat asymptomatic excretors, the impact of passive use of a single polio antiviral drug to treat identified excretors appears limited. Higher drug effectiveness and active efforts to identify long-term excretors will dramatically increase the benefits of polio antiviral drugs. Efforts to develop a second polio antiviral compound to increase polio antiviral effectiveness and/or to maximize the identification and treatment of affected individuals represent important risk management opportunities for the polio endgame. Better data on the survival of PID patients in developing countries and more longitudinal data on their exposure to and recovery from OPV infections would improve our understanding of the risks associated with iVDPV excretors and the benefits of further investments in polio antiviral drugs." @default.
• W2113457384 created "2016-06-24" @default.
• W2113457384 creator A5027109767 @default.
• W2113457384 creator A5035722434 @default.
• W2113457384 creator A5068004603 @default.
• W2113457384 date "2015-09-17" @default.
• W2113457384 modified "2023-10-07" @default.
• W2113457384 title "Modeling the prevalence of immunodeficiency-associated long-term vaccine-derived poliovirus excretors and the potential benefits of antiviral drugs" @default.
• W2113457384 cites W1575665885 @default.
• W2113457384 cites W1610286207 @default.
• W2113457384 cites W1659618301 @default.
• W2113457384 cites W1763607569 @default.
• W2113457384 cites W1814157805 @default.
• W2113457384 cites W1965431513 @default.
• W2113457384 cites W1966965406 @default.
• W2113457384 cites W1978723241 @default.
• W2113457384 cites W1987093411 @default.
• W2113457384 cites W1989333286 @default.
• W2113457384 cites W1992384670 @default.
• W2113457384 cites W1996019523 @default.
• W2113457384 cites W2000937204 @default.
• W2113457384 cites W2008546158 @default.
• W2113457384 cites W2013995625 @default.
• W2113457384 cites W2022472533 @default.
• W2113457384 cites W2024840191 @default.
• W2113457384 cites W2027008928 @default.
• W2113457384 cites W2029776825 @default.
• W2113457384 cites W2035333234 @default.
• W2113457384 cites W2035451300 @default.
• W2113457384 cites W2040399864 @default.
• W2113457384 cites W2041302422 @default.
• W2113457384 cites W2049018139 @default.
• W2113457384 cites W2054025229 @default.
• W2113457384 cites W2058502219 @default.
• W2113457384 cites W2069243463 @default.
• W2113457384 cites W2073672033 @default.
• W2113457384 cites W2078780358 @default.
• W2113457384 cites W2081102729 @default.
• W2113457384 cites W2083190514 @default.
• W2113457384 cites W2096536838 @default.
• W2113457384 cites W2097965467 @default.
• W2113457384 cites W2100566497 @default.
• W2113457384 cites W2102594251 @default.
• W2113457384 cites W2112959636 @default.
• W2113457384 cites W2114533351 @default.
• W2113457384 cites W2115478866 @default.
• W2113457384 cites W2117654306 @default.
• W2113457384 cites W2129900076 @default.
• W2113457384 cites W2134453112 @default.
• W2113457384 cites W2143068295 @default.
• W2113457384 cites W2146139689 @default.
• W2113457384 cites W2146597988 @default.
• W2113457384 cites W2147376810 @default.
• W2113457384 cites W2148158789 @default.
• W2113457384 cites W2149302911 @default.
• W2113457384 cites W2153807635 @default.
• W2113457384 cites W2154773429 @default.
• W2113457384 cites W2155118204 @default.
• W2113457384 cites W2156920603 @default.
• W2113457384 cites W2159041114 @default.
• W2113457384 cites W2189318459 @default.
• W2113457384 cites W2411608886 @default.
• W2113457384 cites W4231125505 @default.
• W2113457384 cites W4300274881 @default.
• W2113457384 cites W4300697770 @default.
• W2113457384 cites W4300989651 @default.
• W2113457384 doi "https://doi.org/10.1186/s12879-015-1115-5" @default.
• W2113457384 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4574619" @default.
• W2113457384 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26382043" @default.
• W2113457384 hasPublicationYear "2015" @default.
• W2113457384 type Work @default.
• W2113457384 sameAs 2113457384 @default.
• W2113457384 citedByCount "38" @default.
• W2113457384 countsByYear W21134573842015 @default.
• W2113457384 countsByYear W21134573842016 @default.
• W2113457384 countsByYear W21134573842017 @default.
• W2113457384 countsByYear W21134573842018 @default.
• W2113457384 countsByYear W21134573842019 @default.
• W2113457384 countsByYear W21134573842020 @default.
• W2113457384 countsByYear W21134573842021 @default.
• W2113457384 countsByYear W21134573842022 @default.
• W2113457384 countsByYear W21134573842023 @default.
• W2113457384 crossrefType "journal-article" @default.
• W2113457384 hasAuthorship W2113457384A5027109767 @default.
• W2113457384 hasAuthorship W2113457384A5035722434 @default.
• W2113457384 hasAuthorship W2113457384A5068004603 @default.
• W2113457384 hasBestOaLocation W21134573841 @default.
• W2113457384 hasConcept C151492266 @default.
• W2113457384 hasConcept C159047783 @default.
• W2113457384 hasConcept C177713679 @default.
• W2113457384 hasConcept C190139176 @default.
• W2113457384 hasConcept C203014093 @default.
• W2113457384 hasConcept C2522874641 @default.
• W2113457384 hasConcept C2779631682 @default.
• W2113457384 hasConcept C2908647359 @default.
• W2113457384 hasConcept C4870876 @default.
• W2113457384 hasConcept C71924100 @default.
• W2113457384 hasConcept C99454951 @default.
• W2113457384 hasConceptScore W2113457384C151492266 @default.
• W2113457384 hasConceptScore W2113457384C159047783 @default.

• next